M Flint Beal

List of Publications by Year in Descending Order

452 papers
68,690 citations
139 h-index
251 g-index
513 ext. papers
73,702 ext. citations
8 avg, IF
7.97 L-index

#	Paper	IF	Citations
452	Altered succinylation of mitochondrial proteins, APP and tau in Alzheimer's disease.. *Nature Communications*, **2022**, 13, 159	17.4	3
451	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model. *Neuropathology and Applied Neurobiology*, **2021**,	5.2	2
450	Changes of Coenzyme A and Acetyl-Coenzyme A Concentrations in Rats after a Single-Dose Intraperitoneal Injection of Hepatotoxic Thioacetamide Are Not Consistent with Rapid Recovery. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	3
449	High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. *Brain Pathology*, **2020**, 30, 945-963	6	4
448	Characterization of a Parkinson's disease rat model using an upgraded paraquat exposure paradigm. *European Journal of Neuroscience*, **2020**, 52, 3242-3255	3.5	8
447	Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. *Nature Reviews Drug Discovery*, **2020**, 19, 609-633	64.1	166
446	Isotope-reinforced polyunsaturated fatty acids improve Parkinson's disease-like phenotype in rats overexpressing -synuclein. *Acta Neuropathologica Communications*, **2020**, 8, 220	7.3	4
445	PGC-1-Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All. *Neurochemical Research*, **2019**, 44, 2423-2434	4.6	16
444	Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease. *European Journal of Neuroscience*, **2019**, 49, 525-532	3.5	19
443	Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human Cells with Mitochondrial DNA Mutations. *Cell Metabolism*, **2018**, 27, 1007-1025.e5	24.6	78
442	Aberrant regulation of the GSK-3/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. *EMBO Molecular Medicine*, **2018**, 10,	12	26
441	Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. *Human Molecular Genetics*, **2018**, 27, 2874-2892	5.6	35
440	Determination of Coenzyme A and Acetyl-Coenzyme A in Biological Samples Using HPLC with UV Detection. *Molecules*, **2017**, 22,	4.8	35
439	Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. *Human Molecular Genetics*, **2017**, 26, 686-701	5.6	47
438	Reductions in the mitochondrial enzyme -ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental?. *Journal of Neurochemistry*, **2016**, 139, 823-838	6	16
437	Mitochondrial dysfunction in Parkinson's disease. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 216-231	6	391
436	Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. *Journal of Neuroscience*, **2016**, 36, 6332-51	6.6	116

435	Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. *Human Molecular Genetics*, **2016**, 25, 2269-2282	5.6	28
434	HPLC determination of -ketoglutaramate [5-amino-2,5-dioxopentanoate] in biological samples. *Analytical Biochemistry*, **2016**, 494, 52-4	3.1	3
433	Preferential PPAR- activation reduces neuroinflammation, and blocks neurodegeneration in vivo. *Human Molecular Genetics*, **2016**, 25, 317-27	5.6	49
432	Simultaneous determination of tricarboxylic acid cycle metabolites by high-performance liquid chromatography with ultraviolet detection. *Analytical Biochemistry*, **2016**, 503, 8-10	3.1	10
431	Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau. *Human Molecular Genetics*, **2015**, 24, 3545-56	5.6	9
430	Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. *Journal of Neuroimaging*, **2015**, 25, 105-10	2.8	30
429	Prospects for neuroprotective therapies in prodromal Huntington's disease. *Movement Disorders*, **2014**, 29, 285-93	7	32
428	PGC-1 overexpression exacerbates -amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. *FASEB Journal*, **2014**, 28, 1745-55	0.9	41
427	Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. *Human Molecular Genetics*, **2014**, 23, 3716-32	5.6	96
426	Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions. *Journal of Cerebral Blood Flow and Metabolism*, **2014**, 34, 1500-10	7.3	38
425	Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. *Parkinsonism and Related Disorders*, **2014**, 20, 545-8	3.6	14
424	Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. *JAMA Neurology*, **2014**, 71, 141-50	17.2	164
423	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. *JAMA Neurology*, **2014**, 71, 543-52	17.2	239
422	PGC-1 mitochondrial dysfunction, and Huntington's disease. *Free Radical Biology and Medicine*, **2013**, 62, 37-46	7.8	131
421	Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. *Antioxidants and Redox Signaling*, **2013**, 18, 139-57	8.4	125
420	Mitochondrial diseases of the brain. *Free Radical Biology and Medicine*, **2013**, 63, 1-29	7.8	305
419	Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. *Molecular and Cellular Neurosciences*, **2013**, 55, 101-14	4.8	105
418	The negative impact of -ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation. *FASEB Journal*, **2013**, 27, 2392-406	0.9	42

417	Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. *Brain*, **2013**, 136, 2432-43	11.2	57
416	Coordinate regulation of mature dopaminergic axon morphology by macroautophagy and the PTEN signaling pathway. *PLoS Genetics*, **2013**, 9, e1003845	6	16
415	A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. *Human Molecular Genetics*, **2013**, 22, 3869-82	5.6	77
414	Nitration of Hsp90 induces cell death. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E1102-11	11.5	98
413	A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson's disease model. *Neurobiology of Disease*, **2012**, 46, 137-46	7.5	32
412	Mitochondrial dysfunction in neurodegenerative diseases. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 342, 619-30	4.7	424
411	Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease. *Antioxidants and Redox Signaling*, **2012**, 16, 855-68	8.4	44
410	Muscling in on PGC-1 for improved quality of life in ALS. *Cell Metabolism*, **2012**, 15, 567-9	24.6	4
409	Antioxidants in Huntington's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 664-74	6.9	106
408	Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. *Human Molecular Genetics*, **2012**, 21, 1124-37	5.6	120
407	NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. *Antioxidants and Redox Signaling*, **2012**, 16, 1033-45	8.4	120
406	Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. *PLoS ONE*, **2012**, 7, e36191	3.7	45
405	Impaired mitochondrial function in psychiatric disorders. *Nature Reviews Neuroscience*, **2012**, 13, 293-307	13.5	323
404	Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. *Annals of Neurology*, **2012**, 71, 850-4	9.4	79
403	Huntington's disease. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2012**, 106, 507-26	3	10
402	Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. *Human Molecular Genetics*, **2012**, 21, 5091-105	5.6	47
401	Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. *Journal of Experimental Medicine*, **2012**, 209, 2501-13	16.6	106
400	Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. *Human Molecular Genetics*, **2012**, 21, 3474-88	5.6	42

399	Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs. *International Journal of Toxicology*, **2012**, 31, 58-69	2.4	4
398	Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice. *Journal of Alzheimeris Disease*, **2012**, 28, 173-82	4.3	35
397	Potential Therapies for Mitochondrial Dysfunction **2012**, 215-230		
396	Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease. *Neurodegenerative Diseases*, **2011**, 8, 496-503	2.3	29
395	Determination of neurotransmitter levels in models of Parkinson's disease by HPLC-ECD. *Methods in Molecular Biology*, **2011**, 793, 401-15	1.4	35
394	Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease. *Neuroscience Letters*, **2011**, 492, 150-4	3.3	19
393	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. *Progress in Neurobiology*, **2011**, 95, 601-13	10.9	27
392	Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. *PLoS ONE*, **2011**, 6, e18568	3.7	297
391	Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. *Journal of Alzheimeris Disease*, **2011**, 27, 211-23	4.3	85
390	Neuroprotective strategies involving ROS in Alzheimer disease. *Free Radical Biology and Medicine*, **2011**, 51, 1014-26	7.8	272
389	Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. *Free Radical Biology and Medicine*, **2011**, 51, 88-96	7.8	156
388	Molecular insights into Parkinson's disease. *F1000 Medicine Reports*, **2011**, 3, 7		37
387	Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature*, **2011**, 480, 547-51	50.4	1294
386	Neuroprotective effects of creatine. *Amino Acids*, **2011**, 40, 1305-13	3.5	123
385	Acute and long-term response of dopamine nigrostriatal synapses to a single, low-dose episode of 3-nitropropionic acid-mediated chemical hypoxia. *Synapse*, **2011**, 65, 339-50	2.4	7
384	DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death. *Antioxidants and Redox Signaling*, **2011**, 14, 2137-50	8.4	21
383	Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. *Journal of Biological Chemistry*, **2011**, 286, 14168-77	5.4	75
382	Parkinson's disease: a model dilemma. *Nature*, **2010**, 466, S8-10	50.4	77

381	Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. *Journal of Experimental Medicine*, **2010**, 207, 117-28	16.6	341
380	Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. *FASEB Journal*, **2010**, 24, 4639-47	0.9	140
379	Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. *Human Molecular Genetics*, **2010**, 19, 3919-35	5.6	229
378	Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. *Human Molecular Genetics*, **2010**, 19, 3190-205	5.6	108
377	Promethazine protects against 3-nitropropionic acid-induced neurotoxicity. *Neurochemistry International*, **2010**, 56, 208-12	4.4	6
376	N-iminoethyl-L-lysine improves memory and reduces amyloid pathology in a transgenic mouse model of amyloid deposition. *Neurochemistry International*, **2010**, 56, 345-51	4.4	12
375	Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2010**, 1802, 122-34	6.9	168
374	Hunting-ton for new proteases: MMPs as the new target?. *Neuron*, **2010**, 67, 171-3	13.9	5
373	Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. *Trends in Neurosciences*, **2010**, 33, 541-9	13.3	176
372	Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. *Experimental Neurology*, **2010**, 225, 74-84	5.7	103
371	Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. *Journal of Alzheimeris Disease*, **2010**, 20 Suppl 2, S633-43	4.3	58
370	Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. *Free Radical Biology and Medicine*, **2010**, 49, 147-58	7.8	134
369	Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. *EMBO Molecular Medicine*, **2010**, 2, 349-70	12	110
368	Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. *Movement Disorders*, **2010**, 25, 1924-8	7	67
367	Mitochondrial therapies for Parkinson's disease. *Movement Disorders*, **2010**, 25 Suppl 1, S155-60	7	40
366	MicroRNA-related cofilin abnormality in Alzheimer's disease. *PLoS ONE*, **2010**, 5, e15546	3.7	77
365	Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. *FASEB Journal*, **2010**, 24, 4639-4647	0.9	11
364	Coenzyme Q10 effects in neurodegenerative disease. *Neuropsychiatric Disease and Treatment*, **2009** , 5, 597-610	3.1	109

363	Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. *PLoS ONE*, **2009**, 4, e5757	3.7	128
362	Impaired PGC-1alpha function in muscle in Huntington's disease. *Human Molecular Genetics*, **2009**, 18, 3048-65	5.6	191
361	Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. *FASEB Journal*, **2009** , 23, 2459-66	0.9	172
360	Urate as a predictor of the rate of clinical decline in Parkinson disease. *Archives of Neurology*, **2009**, 66, 1460-8		265
359	Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. *Antioxidants and Redox Signaling*, **2009**, 11, 2095-104	8.4	125
358	The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. *Antioxidants and Redox Signaling*, **2009**, 11, 2105-18	8.4	125
357	Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins. *Neurobiology of Disease*, **2009**, 36, 320-30	7.5	18
356	Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. *BMC Neuroscience*, **2009**, 10, 109	3.2	110
355	Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. *Free Radical Biology and Medicine*, **2009**, 47, 1019-27	7.8	43
354	Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. *Molecular Neurodegeneration*, **2009**, 4, 34	19	65
353	Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. *Nature Neuroscience*, **2009**, 12, 826-8	25.5	416
352	Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. *Journal of Neurochemistry*, **2009**, 109, 502-12	6	91
351	Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. *Journal of Neurochemistry*, **2009**, 109, 1427-39	6	173
350	Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). *Journal of Neuroscience*, **2009**, 29, 15846-50	6.6	103
349	Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2009**, 1792, 651-63	6.9	178
348	Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. *Neurobiology of Aging*, **2009**, 30, 1587-600	5.6	98
347	Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. *Neurochemistry International*, **2009**, 54, 111-8	4.4	371
346	Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. *Experimental Neurology*, **2009**, 220, 191-7	5.7	58

345	Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 3, S189-94	3.6	70
344	Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. *Journal of Biological Chemistry*, **2009**, 284, 29065-76	5.4	77
343	PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. *PLoS ONE*, **2009**, 4, e4597	3.7	102
342	Metabolomic profiling in LRRK2-related Parkinson's disease. *PLoS ONE*, **2009**, 4, e7551	3.7	112
341	New calpain inhibitor preserves brain architecture in 3-nitropropionic acid (3-NP) model of Huntington disease. *FASEB Journal*, **2009**, 23, 675.7	0.9	
340	Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. *Journal of Neurochemistry*, **2008**, 104, 1613-21	6	104
339	PPAR: a therapeutic target in Parkinson's disease. *Journal of Neurochemistry*, **2008**, 106, 506-18	6	129
338	A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. *Journal of Neurochemistry*, **2008**, 106, 405-15	6	99
337	Oxidative stress biomarkers in sporadic ALS. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, **2008**, 9, 177-83		112
336	Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. *Trends in Molecular Medicine*, **2008**, 14, 45-53	11.5	644
335	Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. *Experimental Neurology*, **2008**, 211, 311-4	5.7	39
334	The urokinase system of plasminogen activator plays a role in amyotrophic lateral sclerosis (ALS) pathogenesis. *Experimental Neurology*, **2008**, 211, 332-3	5.7	1
333	Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. *Nature Clinical Practice Neurology*, **2008**, 4, 600-9		530
332	Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. *International Psychogeriatrics*, **2008**, 20, 67-76	3.4	53
331	Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. *Journal of Neuroscience*, **2008**, 28, 163-76	6.6	129
330	Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia. *Journal of Neuroscience*, **2008**, 28, 9585-97	6.6	24
329	Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7070-5	11.5	436
328	Metabolomic profiling to develop blood biomarkers for Parkinson's disease. *Brain*, **2008**, 131, 389-96	11.2	322

327	Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. *NeuroMolecular Medicine*, **2008**, 10, 275-90	4.6	114
326	Mitochondrial approaches for neuroprotection. *Annals of the New York Academy of Sciences*, **2008**, 1147, 395-412	6.5	189
325	Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. *Annals of the New York Academy of Sciences*, **2008**, 1147, 206-20	6.5	48
324	Excitotoxicity. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2007**, 83, 553-69	3	1
323	A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. *FASEB Journal*, **2007**, 21, 179-87	0.9	163
322	Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. *Muscle and Nerve*, **2007**, 35, 235-42	3.4	208
321	Large stem cell grafts could lead to erroneous interpretations of behavioral results?. *Nature Medicine*, **2007**, 13, 118-9	50.5	11
320	The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **2007**, 102, 991-1000	6	48
319	Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. *Free Radical Biology and Medicine*, **2007**, 42, 1534-42	7.8	36
318	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. *Neurobiology of Disease*, **2007**, 26, 312-22	7.5	58
317	Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 14430-5	11.5	143
316	Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. *Journal of Neuroscience*, **2007**, 27, 12908-15	6.6	71
315	Parkinson's disease. *Human Molecular Genetics*, **2007**, 16 Spec No. 2, R183-94	5.6	612
314	Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. *Journal of Neuroscience*, **2007**, 27, 11758-68	6.6	183
313	Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. *Experimental Neurology*, **2007**, 205, 74-81	5.7	87
312	A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). *Journal of Clinical Pharmacology*, **2007**, 47, 1580-6	2.9	20
311	Mitochondria and neurodegeneration. *Novartis Foundation Symposium*, **2007**, 287, 183-92; discussion 192-6		62
310	Mice lacking alpha-synuclein are resistant to mitochondrial toxins. *Neurobiology of Disease*, **2006**, 21, 541-8	7.5	171

309	Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. *Neurobiology of Disease*, **2006**, 22, 40-9	7.5	144
308	Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. *Neurobiology of Disease*, **2006**, 22, 599-610	7.5	123
307	Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. *Neurobiology of Disease*, **2006**, 24, 455-65	7.5	25
306	Mitochondrial dysfunction and amyotrophic lateral sclerosis. *Muscle and Nerve*, **2006**, 33, 598-608	3.4	97
305	Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neuroscience*, **2006**, 26, 2467-73	6.6	158
304	Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature*, **2006**, 443, 787-95	30.4	4313
303	Oxidative damage in Huntington's disease pathogenesis. *Antioxidants and Redox Signaling*, **2006**, 8, 2061873	7.4	243
302	Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. *Journal of the Neurological Sciences*, **2006**, 251, 44-9	3.2	36
301	The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. *Experimental Neurology*, **2006**, 200, 166-71	5.7	50
300	PGC-1alpha, a new therapeutic target in Huntington's disease?. *Cell*, **2006**, 127, 465-8	56.2	114
299	Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 10793-8	11.5	630
298	Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. *Journal of Neurochemistry*, **2006**, 96, 1349-61	6	179
297	The role of mitochondria in inherited neurodegenerative diseases. *Journal of Neurochemistry*, **2006**, 97, 1659-75	6	142
296	Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **2006**, 98, 1141-8	6	137
295	Parkinsonism genes: culprits and clues. *Journal of Neurochemistry*, **2006**, 99, 1062-72	6	92
294	Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. *Nature Medicine*, **2006**, 12, 1259-68	50.5	677
293	Does the mitochondrial genome play a role in the etiology of Alzheimer's disease?. *Human Genetics*, **2006**, 119, 241-54	6.3	92
292	Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. *Free Radical Research*, **2005**, 39, 383-8	4	61

291	Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. *Neurobiology of Disease*, **2005**, 19, 340-7	7.5	49
290	Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. *Neurobiology of Disease*, **2005**, 20, 701-8	7.5	18
289	Are mitochondria critical in the pathogenesis of Alzheimer's disease?. *Brain Research Reviews*, **2005**, 49, 618-32		222
288	A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. *Experimental Neurology*, **2005**, 191, 86-93	5.7	37
287	Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. *Experimental Neurology*, **2005**, 191, 331-6	5.7	172
286	Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2005**, 26, 585-6	5.6	66
285	Somatic mitochondrial DNA mutations in single neurons and glia. *Neurobiology of Aging*, **2005**, 26, 1343-55	5.6	69
284	Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. *Journal of Neuroscience*, **2005**, 25, 3701-11	6.6	211
283	The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. *Molecular Neurobiology*, **2005**, 31, 43-63	6.2	128
282	Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **2005**, 93, 403-11	6	61
281	Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. *Journal of Neurochemistry*, **2005**, 94, 995-1004	6	168
280	Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. *Journal of Neurochemistry*, **2005**, 94, 1040-53	6	56
279	Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. *Journal of Neurochemistry*, **2005**, 95, 553-62	6	64
278	Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. *Annals of Neurology*, **2005**, 58, 258-65	9.4	114
277	Mitochondria take center stage in aging and neurodegeneration. *Annals of Neurology*, **2005**, 58, 495-505	9.4	742
276	Metabolomic analysis and signatures in motor neuron disease. *Metabolomics*, **2005**, 1, 101-108	4.7	130
275	Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. *Neurochemical Research*, **2005**, 30, 1245-55	4.6	41
274	Biological oxidants and therapeutic antioxidants **2005**, 18-32		

273 Mitochondria, metabolic inhibitors and neurodegeneration **2005**, 33-43

272 Apoptosis in neurodegenerative diseases **2005**, 80-93

271 Protein misfolding and cellular defense mechanisms in neurodegenerative diseases **2005**, 108-130

270 Neurodegenerative disease and the repair of oxidatively damaged DNA **2005**, 131-140

269 Magnetic resonance spectroscopy of neurodegenerative illness **2005**, 301-326

268 Progressive supranuclear palsy **2005**, 663-681 5

267 Current and potential therapeutics in motor neuron diseases **2005**, 772-793

266 Huntington's disease **2005**, 847-860 1

265 Dentatorubral-pallidoluysian atrophy (DRPLA): model for Huntington's disease and other polyglutamine diseases **2005**, 861-870

264 Disorders of the mitochondrial respiratory chain **2005**, 909-926

263 Endogenous free radicals and antioxidants in the brain **2005**, 3-17

262 Excitoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases **2005**, 44-56 1

261 Calcium binding proteins in selective vulnerability of motor neurons **2005**, 65-79 2

260 Copper and zinc in Alzheimer's disease and amyotrophic lateral sclerosis **2005**, 157-165

259 Toxic animal models **2005**, 196-221 5

258 Current and potential treatments of Parkinson's disease **2005**, 612-622

257 Brain iron disorders **2005**, 880-889

256 Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. *CNS and Neurological Disorders*, **2005**, 4, 41-50 120

255	Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. *Neurodegenerative Diseases*, **2005**, 2, 246-54	2.3	157
254	Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. *Journal of Experimental Medicine*, **2005**, 202, 1163-9	16.6	161
253	Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. *Journal of Biological Chemistry*, **2005**, 280, 556-63	5.4	347
252	Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13670-5	11.5	303
251	Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. *Journal of Neuroscience*, **2005**, 25, 2463-70	6.6	193
250	Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2005** , 102, 16535-6	11.5	13
249	Metabolomics: A New Approach Towards Identifying Biomarkers and Therapeutic Targets in CNS Disorders **2005**, 45-61		2
248	Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. *Journal of Neuroscience*, **2004**, 24, 5909-12	6.6	96
247	Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10726-31	11.5	436
246	Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. *Journal of Neuroscience*, **2004**, 24, 10335-42	6.6	162
245	Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. *Methods in Enzymology*, **2004**, 382, 473-87	1.7	37
244	Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neuroscience*, **2004**, 24, 7945-50	6.6	46
243	Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. *Journal of Experimental Medicine*, **2004**, 200, 211-22	16.6	81
242	Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. *PLoS Biology*, **2004**, 2, e327	9.7	304
241	3-Nitropropionic acid-induced neurotoxicity--assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy. *Journal of Neurochemistry*, **2004**, 89, 1206-14	6	27
240	Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. *Journal of Neurochemistry*, **2004**, 89, 1308-12	6	232
239	Experimental therapeutics in transgenic mouse models of Huntington's disease. *Nature Reviews Neuroscience*, **2004**, 5, 373-84	13.5	190
238	Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. *Free Radical Biology and Medicine*, **2004**, 36, 938-42	7.8	76

237	Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. *NeuroMolecular Medicine*, **2004**, 5, 119-32	4.6	50
236	Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. *NeuroMolecular Medicine*, **2004**, 5, 235-41	4.6	74
235	The mitochondrial permeability transition as a target for neuroprotection. *Journal of Bioenergetics and Biomembranes*, **2004**, 36, 309-12	3.7	41
234	Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. *Journal of Bioenergetics and Biomembranes*, **2004**, 36, 381-6	3.7	196
233	The energetics of Huntington's disease. *Neurochemical Research*, **2004**, 29, 531-46	4.6	184
232	Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. *Journal of Neurochemistry*, **2004**, 88, 1352-60	6	78
231	Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. *Journal of Magnetic Resonance Imaging*, **2004**, 19, 34-9	5.6	39
230	Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. *Journal of the Neurological Sciences*, **2004**, 218, 39-45	3.2	23
229	Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **2004**, 88, 576-82	6	148
228	Commentary on "Alpha-synuclein and mitochondria: a tangled skein". *Experimental Neurology*, **2004** , 186, 109-11	5.7	10
227	Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. *Experimental Neurology*, **2004**, 188, 491-4	5.7	151
226	Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. *Neurobiology of Disease*, **2004**, 15, 610-7	7.5	50
225	A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. *Neurobiology of Disease*, **2004**, 17, 250-9	7.5	63
224	Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. *Journal of Neuroscience*, **2004**, 24, 7779-88	6.6	549
223	Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. *Neurobiology of Aging*, **2004**, 25, 71-81	5.6	95
222	Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. *NeuroMolecular Medicine*, **2004**, 6, 87-92	4.6	10
221	Introduction and Historical Notes **2004**, 1-9		
220	Excitotoxicity in Huntington Disease **2004**, 243-249		

219	Mitochondria, oxidative damage, and inflammation in Parkinson's disease. *Annals of the New York Academy of Sciences*, **2003**, 991, 120-31	6.5	383
218	Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. *Stroke*, **2003**, 34, e37-8; author reply e37-8	6.7	26
217	Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. *Endocrinology*, **2003**, 144, 5014-21	4.8	156
216	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. *Journal of Neurochemistry*, **2003**, 86, 267-72	6	49
215	Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. *Journal of Molecular Neuroscience*, **2003**, 21, 191-8	3.3	65
214	Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. *BioFactors*, **2003**, 18, 153-61	6.1	46
213	The oxidative damage theory of aging. *Clinical Neuroscience Research*, **2003**, 2, 305-315		51
212	Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. *Brain Research*, **2003**, 964, 288-94	3.7	131
211	Minocycline enhances MPTP toxicity to dopaminergic neurons. *Journal of Neuroscience Research*, **2003**, 74, 278-85	4.4	125
210	Bioenergetic approaches for neuroprotection in Parkinson's disease. *Annals of Neurology*, **2003**, 53 Suppl 3, S39-47; discussion S47-8	9.4	163
209	Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **2003**, 85, 142-50	6	82
208	Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. *Journal of Neurochemistry*, **2003**, 85, 1359-67	6	143
207	Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. *Journal of Neurochemistry*, **2003**, 87, 272-272	6	1
206	Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. *Nature Biotechnology*, **2003**, 21, 1200-7	44.5	529
205	Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. *Experimental Neurology*, **2003**, 179, 229-35	5.7	28
204	Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. *Neurochemistry International*, **2003**, 43, 191-6	4.4	172
203	Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. *Neuron*, **2003**, 37, 899-909	13.9	535
202	The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic—Reply. *Archives of Neurology*, **2003**, 60, 1172		12

201	Therapeutic effects of cystamine in a murine model of Huntington's disease. *Journal of Neuroscience*, **2002**, 22, 8942-50	6.6	280
200	Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. *Journal of Neuroscience*, **2002**, 22, 1592-9	6.6	348
199	Expression and activity of antioxidants in the brain in progressive supranuclear palsy. *Brain Research*, **2002**, 930, 170-81	3.7	30
198	Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. *Brain Research*, **2002**, 951, 31-5	3.7	25
197	Oxidatively modified proteins in aging and disease. *Free Radical Biology and Medicine*, **2002**, 32, 797-803	7.8	632
196	Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. *Free Radical Biology and Medicine*, **2002**, 32, 920-6	7.8	48
195	Lipid peroxidation in aging brain and Alzheimer's disease. *Free Radical Biology and Medicine*, **2002**, 33, 620-6	7.8	346
194	Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. *Journal of Neurochemistry*, **2002**, 80, 616-25	6	252
193	Cytochrome C and caspase-9 expression in Huntington's disease. *NeuroMolecular Medicine*, **2002**, 1, 183-95	4.6	94
192	Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Archives of Neurology*, **2002**, 59, 1541-50		844
191	High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. *Human Molecular Genetics*, **2002**, 11, 133-45	5.6	262
190	Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. *Archives of Neurology*, **2002**, 59, 794-8		185
189	Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. *American Journal of Pathology*, **2002**, 161, 1869-79	5.8	573
188	Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. *Experimental Neurology*, **2002**, 176, 262-5	5.7	41
187	Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. *Experimental Neurology*, **2002**, 178, 13-20	5.7	102
186	Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. *Neurobiology of Disease*, **2002**, 11, 410-24	7.5	105
185	Sequence analysis of the entire mitochondrial genome in Parkinson's disease. *Biochemical and Biophysical Research Communications*, **2002**, 290, 1593-601	3.4	62
184	Coenzyme Q10 as a possible treatment for neurodegenerative diseases. *Free Radical Research*, **2002**, 36, 455-60	4	112

183	Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. *Journal of Biological Chemistry*, **2002**, 277, 29626-33	5.4	442
182	Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. *American Journal of Human Genetics*, **2002**, 70, 1152-71	11	449
181	Toxin-induced mitochondrial dysfunction. *International Review of Neurobiology*, **2002**, 53, 243-79	4.4	15
180	N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. *Journal of Neurochemistry*, **2001**, 79, 1109-12	6	66
179	Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. *Journal of Neurochemistry*, **2001**, 79, 1246-9	6	192
178	Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. *Journal of Neuroscience*, **2001**, 21, 2561-70	6.6	405
177	Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. *Journal of Neurochemistry*, **2001**, 77, 383-90	6	100
176	Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. *Journal of Neuroscience Research*, **2001**, 66, 1028-34	4.4	70
175	Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. *Annals of Neurology*, **2001**, 49, 561-574	9.4	196
174	Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. *Annals of Neurology*, **2001**, 50, 112-7	9.4	72
173	Age and sex influence on oxidative damage and functional status in human skeletal muscle. *Journal of Muscle Research and Cell Motility*, **2001**, 22, 345-51	3.5	113
172	Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. *Journal of Molecular Neuroscience*, **2001**, 17, 89-96	3.3	47
171	Experimental models of Parkinson's disease. *Nature Reviews Neuroscience*, **2001**, 2, 325-34	13.5	476
170	In vivo regulation of oxidative phosphorylation in cells harboring a stop-codon mutation in mitochondrial DNA-encoded cytochrome c oxidase subunit I. *Journal of Biological Chemistry*, **2001**, 276, 46925-32	5.4	62
169	Huntington's Disease **2001**, 711-725		
168	Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. *Journal of Neuroscience*, **2001**, 21, 9519-28	6.6	256
167	Lipoic acid improves survival in transgenic mouse models of Huntington's disease. *NeuroReport*, **2001**, 12, 3371-3	1.7	93
166	Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. *Journal of Neurochemistry*, **2000**, 74, 2108-19	6	130

165	The role of mitochondria in the pathogenesis of neurodegenerative diseases. *Brain Pathology*, **2000**, 10, 462-72	6	79
164	Oxidative metabolism. *Annals of the New York Academy of Sciences*, **2000**, 924, 164-9	6.5	31
163	Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. *Journal of Neurochemistry*, **2000**, 75, 847-52	6	36
162	Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. *Journal of Neurochemistry*, **2000**, 74, 878-81	6	81
161	Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. *Journal of Neuroscience*, **2000**, 20, 4389-97	6.6	454
160	MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. *NeuroReport*, **2000**, 11, 211-3	1.7	214
159	Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. *NeuroReport*, **2000**, 11, 1265-8	1.7	55
158	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. *NeuroReport*, **2000**, 11, 2491-3	1.7	121
157	Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. *Annals of Neurology*, **2000**, 47, 447-455	9.4	66
156	Amyotrophic lateral sclerosis: Transgenic model and novel neuroprotective agent. *Neuroscience Research Communications*, **2000**, 26, 215-226		1
155	Increased oxidative damage to DNA in ALS patients. *Free Radical Biology and Medicine*, **2000**, 29, 652-8	7.8	245
154	Neuroprotective and neurorestorative strategies for neuronal injury. *Neurotoxicity Research*, **2000**, 2, 71-84	4.3	12
153	Prospects for redox-based therapy in neurodegenerative diseases. *Neurotoxicity Research*, **2000**, 2, 229-37	4.3	9
152	Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. *Journal of Neuroscience*, **2000**, 20, 1-7	6.6	1886
151	Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. *Journal of Neural Transmission Supplementum*, **2000**, 59, 133-54		176
150	The Neuroprotective Properties of Creatine in Animal Models of Neurodegenerative Diseases. *Medical Science Symposia Series*, **2000**, 101-118		0
149	Systemic Administration of 3-Nitropropionic Acid **2000**, 301-332		1
148	Oxidative stress in Huntington's disease. *Brain Pathology*, **1999**, 9, 147-63	6	353

147	Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. *Journal of Neurochemistry*, **1999**, 73, 881-4	6	47
146	Bioenergetics in Huntington's disease. *Annals of the New York Academy of Sciences*, **1999**, 893, 203-13	6.5	89
145	Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. *Nature Medicine*, **1999**, 5, 347-50	50.5	611
144	The cerebral metabolic consequences of nitric oxide synthase deficiency: glucose utilization in endothelial and neuronal nitric oxide synthase null mice. *Journal of Cerebral Blood Flow and Metabolism*, **1999**, 19, 144-8	7.3	12
143	Mitochondria in neurodegeneration: bioenergetic function in cell life and death. *Journal of Cerebral Blood Flow and Metabolism*, **1999**, 19, 231-45	7.3	242
142	Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. *Journal of Cerebral Blood Flow and Metabolism*, **1999**, 19, 351-69	7.3	294
141	Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. *BioFactors*, **1999**, 9, 261-6	6.1	85
140	A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. *BioFactors*, **1999**, 9, 267-72	6.1	80
139	Huntingtin aggregates may not predict neuronal death in Huntington's disease. *Annals of Neurology* , **1999**, 46, 842-849	9.4	309
138	Riluzole therapy in Huntington's disease (HD). *Movement Disorders*, **1999**, 14, 326-30	7	115
137	Area-Specific Differences in OH8dG and mtDNA4977 Levels in Alzheimer Disease Patients and Aged Controls. *Rejuvenation Research*, **1999**, 2, 209-216		8
136	Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. *Neuroscience Letters*, **1999**, 259, 21-4	3.3	103
135	Oxidative stress is attenuated in mice overexpressing BCL-2. *Neuroscience Letters*, **1999**, 262, 33-6	3.3	53
134	Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. *NeuroReport*, **1999**, 10, 635-8	1.7	73
133	Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. *NeuroReport*, **1999**, 10, 2881-6	1.7	78
132	Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. *Journal of Histochemistry and Cytochemistry*, **1998**, 46, 731-5	3.4	217
131	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. *Cell Death and Differentiation*, **1998**, 5, 847-57	12.7	89
130	Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. *Annals of Neurology*, **1998**, 44, S110-4	9.4	200

129	The neurotoxicity of amyloid beta protein in aged primates. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis* , **1998**, 5, 1-9	2.7	49
128	Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **1998**, 71, 281-7	6	103
127	Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **1998**, 71, 1321-4	6	125
126	Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. *Journal of Neurochemistry*, **1998**, 71, 2634-7	6	94
125	Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. *Journal of Neurochemistry*, **1998**, 71, 2642-4	6	70
124	Manganese superoxide dismutase overexpression attenuates MPTP toxicity. *Neurobiology of Disease*, **1998**, 5, 253-8	7.5	131
123	Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. *Neurology*, **1998**, 50, 793-5	6.5	92
122	Glutamate toxicity in chronic neurodegenerative disease. *Progress in Brain Research*, **1998**, 116, 331-47	2.9	88
121	Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. *Journal of Neuroscience*, **1998**, 18, 156-63	6.6	365
120	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. *Journal of Neuroscience*, **1998**, 18, 8145-52	6.6	181
119	Mitochondrial Dysfunction and Neurodegenerative Diseases **1998**, 265-296		
118	Mitochondrial Dysfunction and Alzheimer□ Disease. *Advances in Behavioral Biology*, **1998**, 59-66		1
117	Oxidative Damage in Neurodegenerative Diseases. *Neuroscientist*, **1997**, 3, 21-27	7.6	50
116	Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. *Journal of Neuroscience*, **1997**, 17, 3052-63	6.6	131
115	Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. *Journal of Neuroscience*, **1997**, 17, 6908-17	6.6	175
114	The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. *Molecular and Cellular Biochemistry*, **1997**, 174, 193-197	4.2	139
113	Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. *Molecular and Chemical Neuropathology*, **1997**, 31, 53-64		168
112	Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. *Annals of Neurology*, **1997**, 41, 160-5	9.4	371

111	Cortical peptide changes in Huntington's disease may be independent of striatal degeneration. *Annals of Neurology*, **1997**, 41, 540-7	9.4	19
110	Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. *Annals of Neurology*, **1997**, 41, 646-53	9.4	735
109	Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. *Annals of Neurology*, **1997**, 42, 261-4	9.4	235
108	Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. *Annals of Neurology*, **1997**, 42, 326-34	9.4	221
107	Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. *Annals of Neurology*, **1997**, 42, 644-54	9.4	512
106	Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. *Magnetic Resonance in Medicine*, **1997**, 38, 389-98	4.4	216
105	Iodoacetate produces striatal excitotoxic lesions. *Journal of Neurochemistry*, **1997**, 69, 285-9	6	35
104	Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **1997**, 69, 2064-74	6	551
103	The Role of Oxidative Processes and Metal Ions in Aging and Alzheimer□ Disease **1997**, 237-275		8
102	Therapeutic Strategies in Alzheimer□ Disease **1997**, 329-336		
101	The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases **1997**, 193-197		2
100	Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. *Journal of Neurochemistry*, **1996**, 67, 430-3	6	67
99	Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives. *Biological Psychiatry*, **1996**, 39, 1061-3	7.9	14
98	Mitochondria, free radicals, and neurodegeneration. *Current Opinion in Neurobiology*, **1996**, 6, 661-6	7.6	372
97	Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. *Journal of Neuroscience*, **1996**, 16, 3019-25	6.6	220
96	NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease. *NeuroReport*, **1996**, 7, 2639-42	1.7	48
95	NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. *Brain Research*, **1996**, 713, 178-85	3.7	92
94	Increased 3-nitrotyrosine in brains of Apo E-deficient mice. *Brain Research*, **1996**, 718, 181-4	3.7	55

93	Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. *Nature Genetics*, **1996**, 13, 43-7	36.3	1042
92	Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. *Nature Medicine*, **1996**, 2, 1017-21	50.5	396
91	Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. *Journal of Cerebral Blood Flow and Metabolism*, **1996**, 16, 450-61	7.3	76
90	Bioenergetics in Oxidative Damage in Neurodegenerative Diseases **1996**, 171-179		2
89	Therapeutic effects of nitric oxide synthase inhibition in neuronal injury **1996**, 91-101		2
88	Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. *Journal of Neurochemistry*, **1995**, 64, 936-9	6	332
87	Involvement of free radicals in excitotoxicity in vivo. *Journal of Neurochemistry*, **1995**, 64, 2239-47	6	265
86	Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **1995**, 64, 2366-9	6	90
85	3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. *Journal of Neurochemistry*, **1995**, 65, 919-22	6	133
84	Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. *Journal of Cerebral Blood Flow and Metabolism*, **1995**, 15, 948-52	7.3	55
83	Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. *Journal of Cerebral Blood Flow and Metabolism*, **1995**, 15, 619-23	7.3	81
82	CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain. *Neuron*, **1995**, 15, 1193-201	13.9	161
81	Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. *Experimental Neurology*, **1995**, 132, 279-83	5.7	83
80	Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. *Annals of the New York Academy of Sciences*, **1995**, 765, 100-10; discussion 116-8	6.5	24
79	Aging, energy, and oxidative stress in neurodegenerative diseases. *Annals of Neurology*, **1995**, 38, 357-66	9.4	1201
78	Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. *Journal of Neurochemistry*, **1994**, 63, 2179-84	6	383
77	Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. *Annals of Neurology*, **1994**, 36, 747-51	9.4	893
76	Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. *Annals of Neurology*, **1994**, 36, 882-8	9.4	172

75	3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. *Journal of Cerebral Blood Flow and Metabolism*, **1994**, 14, 1024-9	7.3	35
74	Huntington's disease, energy, and excitotoxicity. *Neurobiology of Aging*, **1994**, 15, 275-6	5.6	57
73	Malonate produces striatal lesions by indirect NMDA receptor activation. *Brain Research*, **1994**, 647, 161-7	3.7	87
72	Neurochemistry and toxin models in Huntington's disease. *Current Opinion in Neurology*, **1994**, 7, 542-7	7.1	91
71	Mitochondrial dysfunction in movement disorders. *Current Opinion in Neurology*, **1994**, 7, 333-9	7.1	66
70	Mitochondrial Dysfunction, Aging, and Huntington's Disease **1994**, 111-126		
69	Mechanisms of Neuronal Degeneration in Huntington's Disease. *Advances in Behavioral Biology*, **1994**, 149-161		6
68	Delayed administration of basic fibroblast growth factor protects against N-methyl-D-aspartate neurotoxicity in neonatal rats. *European Journal of Pharmacology*, **1993**, 232, 295-7	5.3	32
67	NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. *NeuroReport*, **1993** , 4, 387-90	1.7	85
66	Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. *Annals of Neurology*, **1993**, 34, 609-16	9.4	642
65	Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats. *Journal of Cerebral Blood Flow and Metabolism*, **1993**, 13, 221-8	7.3	199
64	Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. *Journal of Neurochemistry*, **1993**, 61, 1147-50	6	261
63	Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. *Journal of Neurochemistry*, **1993**, 60, 356-9	6	341
62	Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. *Journal of Neurochemistry*, **1993**, 61, 2322-5	6	473
61	Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. *Brain Research Bulletin*, **1992**, 28, 233-8	3.9	91
60	The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. *Neuroscience Letters*, **1992**, 146, 115-8	3.3	42
59	Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. *Journal of the Neurological Sciences*, **1992**, 108, 80-7	3.2	178
58	Huntington's disease and neurotoxins. *Annals of the New York Academy of Sciences*, **1992**, 648, 169-75	6.5	10

57	Developmental changes in brain kynurenic acid concentrations. *Developmental Brain Research*, **1992**, 68, 136-9		54
56	Mechanisms of excitotoxicity in neurologic diseases. *FASEB Journal*, **1992**, 6, 3338-3344	0.9	328
55	1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. *Journal of Neurochemistry*, **1992**, 58, 1975-8	6	155
54	Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. *Nature Genetics*, **1992**, 2, 324-9	36.3	778
53	Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. *Journal of Cerebral Blood Flow and Metabolism*, **1992**, 12, 400-7	7.3	112
52	Inability of □amyloid (25□35) to bind to central nervous system neurokinin 1 receptors. *Drug Development Research*, **1992**, 27, 441-444	5.1	7
51	Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. *Annals of Neurology*, **1992**, 31, 119-30	9.4	908
50	The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex. *Annals of Neurology*, **1992**, 32, 526-34	9.4	50
49	Comparative behavioral and neurochemical studies with striatal kainic acid- or quinolinic acid-lesioned rats. *Pharmacology Biochemistry and Behavior*, **1991**, 39, 473-8	3.9	41
48	Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. *Journal of Neurochemistry*, **1991**, 57, 1068-73	6	107
47	Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. *Annals of Neurology*, **1991**, 29, 162-7	9.4	74
46	Effects of aging on quinolinic acid lesions in rat striatum. *Brain Research*, **1991**, 562, 276-80	3.7	18
45	Global ischemia induces NMDA receptor-mediated c-fos expression in neurons resistant to injury in gerbil hippocampus. *Brain Research*, **1991**, 542, 343-7	3.7	94
44	Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. *Journal of Neurochemistry*, **1990**, 55, 1327-39	6	266
43	Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. *Annals of Neurology*, **1990**, 27, 620-5	9.4	201
42	Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease. *Annals of Neurology*, **1990**, 28, 157-61	9.4	103
41	Multiple cranial-nerve palsies: a diagnostic challenge. *New England Journal of Medicine*, **1990**, 322, 461-3	59.2	15
40	Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. *Brain Research Bulletin*, **1990**, 25, 623-7	3.9	32

39	Homocysteic acid lesions in rat striatum spare somatostatin-neuropeptide Y (NADPH-diaphorase) neurons. *Neuroscience Letters*, **1990**, 108, 36-42	3.3	42
38	Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures. *Brain Research*, **1990**, 521, 254-64	3.7	65
37	Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. *Synapse*, **1989**, 3, 38-47	2.4	182
36	Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases. *Brain Research*, **1989**, 486, 387-90	3.7	19
35	Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease. *Annals of Neurology*, **1988**, 23, 105-14	9.4	197
34	Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. *Annals of Neurology*, **1988**, 23, 562-9	9.4	73
33	Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. *Annals of Neurology*, **1988**, 24, 647-50	9.4	36
32	Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes. *Synapse*, **1988**, 2, 463-7	2.4	19
31	Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex. *Journal of Neurochemistry*, **1988**, 51, 1935-41	6	44
30	Amino acid and neuropeptide neurotransmitters in Huntington's disease cerebellum. *Brain Research*, **1988**, 454, 393-6	3.7	12
29	A detailed examination of substance P in pathologically graded cases of Huntington's disease. *Journal of the Neurological Sciences*, **1988**, 84, 51-61	3.2	46
28	Distribution of galanin-like immunoreactivity in baboon brain. *Peptides*, **1988**, 9, 847-51	3.8	40
27	Age-related disruption of classical conditioning: a model systems approach to memory disorders. *Neurobiology of Aging*, **1988**, 9, 535-46	5.6	51
26	Neuropeptide Abnormalities in Alzheimer's and Huntington's Diseases **1988**, 199-212		1
25	Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. *Journal of Neuropathology and Experimental Neurology*, **1987**, 46, 12-27	3.1	242
24	A comparison of somatostatin and neuropeptide Y distribution in monkey brain. *Brain Research*, **1987**, 405, 213-9	3.7	44
23	Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. *Brain Research*, **1987**, 411, 162-6	3.7	231
22	The effect of amphetamine on the in vivo release of dopamine, somatostatin and neuropeptide Y from rat caudate nucleus. *Brain Research*, **1987**, 411, 200-3	3.7	54

21	Effect of cysteamine on somatostatin and neuropeptide Y in rat striatum and cortical synaptosomes. *Brain Research*, **1987**, 401, 359-64	3.7	13
20	Idiopathic cranial polyneuropathy. A fifteen-year experience. *Brain*, **1987**, 110 (Pt 1), 197-211	11.2	46
19	Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia. *Neurochemical Pathology*, **1987**, 6, 169-76		17
18	Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. *Annals of Neurology*, **1986**, 20, 282-8	9.4	147
17	Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease. *Annals of Neurology*, **1986**, 20, 489-95	9.4	84
16	Neuropeptides in neurological disease. *Annals of Neurology*, **1986**, 20, 547-65	9.4	150
15	A postmortem study of amino acid neurotransmitters in Alzheimer's disease. *Annals of Neurology*, **1986**, 20, 616-21	9.4	123
14	Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. *Nature*, **1986**, 321, 168-71	50.4	1147
13	Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. *Brain Research*, **1986**, 397, 386-8	3.7	22
12	Reduced concentrations of arginine vasopressin and MHPG in lumbar CSF of patients with Korsakoff's psychosis. *Life Sciences*, **1986**, 38, 2301-6	6.8	16
11	Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. *Brain Research*, **1986**, 368, 380-3	3.7	34
10	A comparison of regional somatostatin and neuropeptide Y distribution in rat striatum and brain. *Brain Research*, **1986**, 377, 240-5	3.7	39
9	Neuropeptides in Alzheimer's Disease: Clinical implications. *Neurologic Clinics*, **1986**, 4, 753-768	4.5	7
8	Effects of lesions in the amygdala and periventricular hypothalamus on striatal somatostatin-like immunoreactivity. *Brain Research*, **1985**, 330, 309-16	3.7	20
7	Topographical dopamine and serotonin distribution and turnover in rat striatum. *Brain Research*, **1985**, 358, 10-5	3.7	60
6	Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease. *Brain Research*, **1985**, 361, 135-45	3.7	34
5	Implications of neuropeptides in neurological diseases. *Peptides*, **1984**, 5 Suppl 1, 255-62	3.8	27
4	Depletion of striatal somatostatin by local cysteamine injection. *Brain Research*, **1984**, 308, 319-24	3.7	22

3	Regional somatostatin distribution in the rat striatum. *Brain Research*, **1983**, 278, 103-8	3.7	53
2	Effects of lesions on somatostatin-like immunoreactivity in the rat striatum. *Brain Research*, **1983**, 266, 67-73	3.7	58
1	Primary lateral sclerosis: a case report. *Archives of Neurology*, **1981**, 38, 630-3		79